Disturbed cholesterol homeostasis plays critical roles in the development of multiple
diseases, such as cardiovascular diseases (CVD), neurodegenerative diseases and …

Background High lipoprotein (a) concentrations present in 10%–20% of the population have
long been linked to increased risk of ischemic cardiovascular disease. It is unclear whether …

2168 Circulation December 1, 2015 sufficient evidence for health benefit exists to implement
case finding via family history–based screening, cascade screening, or other strategies …

Excess hepatic storage of triglycerides is considered a benign condition, but nonalcoholic
steatohepatitis (NASH) may progress to fibrosis and promote atherosclerosis. Carriers of the …

Familial hypercholesterolaemia is common in individuals who had a myocardial infarction at
a young age. As many as one in 200 people could have heterozygous familial …

Background: Evolocumab and other anti-PCSK9 antibodies reduced adverse cardiovascular
outcomes in clinical trials of high-risk patients over< 3 years median treatment duration …

Familial hypercholesterolemia (FH) is a genetic disorder resulting from mutations in genes
encoding proteins involved in the metabolism of low density lipoproteins (LDL) and …

Notwithstanding the effectiveness of lowering LDL cholesterol, residual CVD risk remains in
high-risk populations, including patients with diabetes, likely contributed to by non-LDL lipid …

Several new or emerging drugs for dyslipidemia owe their existence, in part, to human
genetic evidence, such as observations in families with rare genetic disorders or in …

The introduction of statins≈ 30 years ago ushered in the era of lipid lowering as the most
effective way to reduce risk of atherosclerotic cardiovascular disease. Nonetheless, residual …